000182490 001__ 182490
000182490 005__ 20240229145720.0
000182490 0247_ $$2doi$$a10.1016/j.jhepr.2022.100602
000182490 0247_ $$2pmid$$apmid:36352895
000182490 0247_ $$2pmc$$apmc:PMC9638835
000182490 0247_ $$2altmetric$$aaltmetric:136634040
000182490 037__ $$aDKFZ-2022-02685
000182490 041__ $$aEnglish
000182490 082__ $$a610
000182490 1001_ $$0P:(DE-He78)19b0ec1cea271419d9fa8680e6ed6865$$aHemminki, Kari$$b0$$eFirst author$$udkfz
000182490 245__ $$aLong-term survival trends for primary liver and pancreatic cancers in the Nordic countries.
000182490 260__ $$aAmsterdam$$bElsevier$$c2022
000182490 3367_ $$2DRIVER$$aarticle
000182490 3367_ $$2DataCite$$aOutput Types/Journal article
000182490 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1668083494_6565
000182490 3367_ $$2BibTeX$$aARTICLE
000182490 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000182490 3367_ $$00$$2EndNote$$aJournal Article
000182490 500__ $$a#EA:C020#
000182490 520__ $$aLiver cancer (LC) and pancreatic cancer (PC) are often diagnosed at an advanced stage resulting in high mortality. High-quality survival data are rarely available for trend analyses over a long period.The Danish, Finnish, Norwegian, and Swedish cancer data were accessed at the NORDCAN database. We analysed relative 1- and 5-year survival trends in LC and PC between years 1970 and 2019.Relative 1-year survival in LC for Nordic men and women was about 10% in the period between 1970 and 1974, and it increased moderately by year 2000 and steeply thereafter, eventually reaching 40-50%. The patterns in 5-year survival were similar, but after the year 2000, survival in Norway and Sweden increased steeply to 23%, whereas survival in Denmark and Finland lagged behind, reaching 10% to 15%. The patterns for PC also showed rapid improvement after the year 2000, with 1-year survival reaching 30% to 40% and 5-year survival reaching 10% for Finland and 15% for Norway and Sweden. Survival was best for patients diagnosed before age 50 years, and it was worst for older patients. For both cancers the difference between 1- and 5-year survival increased with time.Survival in LC and PC improved first modestly and then steeply over the 50-year period covered. The increase in 5-year survival was less than that of 1-year survival. The survival gains were most likely the result of earlier diagnosis, improved treatment, and better organised supportive care. The challenges are to keep up these positive trends, to extend survival benefits past Year 1, and to obtain similar results in elderly patients. Primary prevention through avoidance of risk factors would reduce case numbers.Liver and pancreatic cancers are among the most lethal of all cancers. In 50 years, survival in these cancers has slowly improved, and in the past 20 years, the development has been increasingly favourable. Widespread adoption of healthy lifestyles will be key to reducing the risk of these cancers.
000182490 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000182490 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000182490 650_7 $$2Other$$aCI5, Cancer Incidence in Five Continents
000182490 650_7 $$2Other$$aDK, Denmark
000182490 650_7 $$2Other$$aFI, Finland
000182490 650_7 $$2Other$$aHepatocellular carcinoma
000182490 650_7 $$2Other$$aIARC, International Agency for Research on Cancer
000182490 650_7 $$2Other$$aICD, International Classification of Diseases
000182490 650_7 $$2Other$$aICSS, International Cancer Survival Standard
000182490 650_7 $$2Other$$aIPMN, intraductal papillary mucinous neoplasm
000182490 650_7 $$2Other$$aLC, liver cancer
000182490 650_7 $$2Other$$aMortality
000182490 650_7 $$2Other$$aNO, Norway
000182490 650_7 $$2Other$$aPAF, population attributable fraction
000182490 650_7 $$2Other$$aPC, pancreatic cancer
000182490 650_7 $$2Other$$aRelative survival
000182490 650_7 $$2Other$$aRisk factors
000182490 650_7 $$2Other$$aSE, Sweden
000182490 650_7 $$2Other$$aTreatment
000182490 7001_ $$0P:(DE-He78)f26164c08f2f14abcf31e52e13ee3696$$aFörsti, Asta$$b1$$udkfz
000182490 7001_ $$aHemminki, Otto$$b2
000182490 7001_ $$aLiska, Vaclav$$b3
000182490 7001_ $$aHemminki, Akseli$$b4
000182490 773__ $$0PERI:(DE-600)2972660-8$$a10.1016/j.jhepr.2022.100602$$gVol. 4, no. 12, p. 100602 -$$n12$$p100602$$tJHEP reports$$v4$$x2589-5559$$y2022
000182490 909CO $$ooai:inrepo02.dkfz.de:182490$$pVDB
000182490 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)19b0ec1cea271419d9fa8680e6ed6865$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000182490 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f26164c08f2f14abcf31e52e13ee3696$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000182490 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000182490 9141_ $$y2022
000182490 915__ $$0LIC:(DE-HGF)CCBYNCNDNV$$2V:(DE-HGF)$$aCreative Commons Attribution-NonCommercial-NoDerivs CC BY-NC-ND (No Version)$$bDOAJ$$d2020-09-06
000182490 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2020-09-06
000182490 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2020-09-06
000182490 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJHEP REP : 2021$$d2022-11-26
000182490 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-26
000182490 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-26
000182490 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2021-07-05T06:57:05Z
000182490 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2021-07-05T06:57:05Z
000182490 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review$$d2021-07-05T06:57:05Z
000182490 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-26
000182490 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-26
000182490 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2022-11-26
000182490 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2022-11-26
000182490 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bJHEP REP : 2021$$d2022-11-26
000182490 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x0
000182490 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x1
000182490 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x2
000182490 9200_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x0
000182490 980__ $$ajournal
000182490 980__ $$aVDB
000182490 980__ $$aI:(DE-He78)C020-20160331
000182490 980__ $$aI:(DE-He78)B062-20160331
000182490 980__ $$aI:(DE-He78)HD01-20160331
000182490 980__ $$aUNRESTRICTED